CHORDC1

Across TCGA pan-cancer cohorts, CHORDC1 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated CHORDC1 data layer compared with 26 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher CHORDC1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CHORDC1 expression acts as an unfavorable survival marker.

ESCA, HNSC, and SKCM are the cancer types where CHORDC1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.117	0.703	<.001	36	view →
HNSC	OS	Median	All	0.169	0.710	.008	24	view →
SKCM	DFS	Median	All	0.282	0.739	.001	19	view →
OV	OS	Median	II,III,IV	0.308	0.691	.033	18	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
READ	OS	Median	III,IV	0.287	0.748	.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
COAD	DFS	Median	III,IV	0.170	0.697	.030	6	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

CHORDC1–ESCA (OS)

Open the ESCA breakdown →